Zhaohui L. Arter, MD

Hematology-Oncology, Medical Oncology

View full profile

Related Videos

Video

Survey of actionable driver mutations KRAS and EGFR in non–small cell lung cancer

Molecularly targeted therapies have advanced treatment for certain cancers, such as lung cancer with specific EGFR or KRAS mutations. However, oftentimes the tumor becomes eventually treatment resistant.

UCI Health

As the clinical enterprise of the University of California, Irvine, UCI Health integrates leading-edge research with compassionate healthcare services. Known for its exceptional physicians, state-of-the-art facilities and commitment to innovation, UCI Health delivers comprehensive medical care, ranging from primary care to specialized treatments. With a focus on patient-centric approaches, we strive to improve lives through education, research breakthroughs and medical expertise.